{"entity":{"id":"nct07108309","kind":"trial","name":"BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer","aka":[],"tldr":"A phase 2 trial of BCD-236 in triple-negative breast cancer, run by Biocad, now recruiting.","summary":"BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer is a phase 2 interventional study registered as NCT07108309 by Biocad, with 124 participants planned, started 2024-07-15 and due to reach its primary completion in 2025-12. Interventions recorded: BCD-236 and Chemotherapy.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07108309","url":"https://clinicaltrials.gov/study/NCT07108309"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["tnbc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["biocad"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07108309","phase":"2","setting":"A Randomized, Open-label, Comparative Clinical Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer","sponsor":"Biocad","enrolled":124,"outcomes":[]},"route":"/trials/nct07108309/","neighbours":{"cancer":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"company":[{"id":"biocad","kind":"company","name":"Biocad","route":"/companies/biocad/"}]}}